<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904432</url>
  </required_header>
  <id_info>
    <org_study_id>2021-06</org_study_id>
    <nct_id>NCT04904432</nct_id>
  </id_info>
  <brief_title>PLIN1 Variants in Precocious ACS (SCAPLIN)</brief_title>
  <official_title>Involvement of Perilipin-1 Variants in Precocious Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to identify a genetic predisposition factor of precocious acute coronary&#xD;
      syndrome occurrence (ACS). ACS is a major public health problem and the first cause of&#xD;
      mortality in the world. It can be due to several risk factor such as heredity. the&#xD;
      investigators make the hypothesis that occurrence of early ACS (defined as &lt;50yo for men and&#xD;
      &lt;55yo for women) could be the initiatory event of a mild form of genetic lipodystrophy . Our&#xD;
      previous study shown an occurrence risk of ACS about 8.3 in patients carrying a mutation in&#xD;
      the PLIN1 gene versus patients without a mutation. The PLIN1 gene encode for perilipin 1&#xD;
      protein localized on the lipid droplet surface. This protein phosphorylation activates the&#xD;
      triglycerides lipolysis. Our goals in this study are multiple: to validate the high frequency&#xD;
      of mutations in this gene in patients with early ACS, to determine differences in&#xD;
      triglycerides metabolism and also relapse rate between carrier and non-carrier patients of&#xD;
      mutation in PLIN1. Our first aim will be to carry out the inclusion of 200 patients with&#xD;
      precocious ACS. This will allow us to obtain around 15 patients carrying a mutation in the&#xD;
      PLIN1 gene based on our previous study. the investigators will reprogramme patients' cells&#xD;
      (carrying or not a PLIN1 mutation) in human Induce Pluripotent Stem cells (hIPSc). These&#xD;
      hIPSc will be differentiated in cell types of interest as adipocytes or macrophages. the&#xD;
      investigators will then study triglycerides metabolism (lipid droplet formation, localization&#xD;
      and phosphorylation of perlipin 1) in these cells and atheroma plaque formation. Finally, the&#xD;
      investigators will study clinical data such as relapse rate and searching for correlation&#xD;
      with PLIN1 mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PLIN1 mutation</measure>
    <time_frame>1 month</time_frame>
    <description>sequencing PLIN1 gene to look for mutation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid droplets</measure>
    <time_frame>3 years</time_frame>
    <description>Analyze size of lipid droplets in differentiated hIPS cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>Ischaemic relapse rate during the year of classical following-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>young ACS patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PLIN1 gene sequencing</intervention_name>
    <description>One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations</description>
    <arm_group_label>young ACS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of the patient when ACS occurs (between 18 and 50yo for men, between 18 and 55yo&#xD;
             for women)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men &lt;18yo or &gt;50yo&#xD;
&#xD;
          -  Women &lt;18yo or &gt;55yo&#xD;
&#xD;
          -  ACS causes (toxic, coronary dissection)&#xD;
&#xD;
          -  Congenital cardiac malformations&#xD;
&#xD;
          -  Familial hypercholesterolaemia&#xD;
&#xD;
          -  Pregnancy, breast-feeding women or vulnerable profile.&#xD;
&#xD;
          -  Patient refusal to participate or previously included in a clinical research trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie GARRIDO-PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie BONELLO-PALOT</last_name>
    <phone>04 91 38 77 87</phone>
    <phone_ext>+33</phone_ext>
    <email>nathalie.bonello@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra GIULIANI</last_name>
    <phone>04 91 38 28 70</phone>
    <phone_ext>+33</phone_ext>
    <email>Alexandra.GIULIANI@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie BONELLO-PALOT, Pharm.D, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent BONELLO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

